Thus, herein we report new in vivo findings of our newly reported IFBOs that manifest an anti-tumor therapeutic effect by the favorable regulation of the IL-6-JAK2-STAT3 signaling nexus during NDEA-induced HCC condition. This evidence concerns the gene JAK2 and hepatocellular carcinoma.